This study is testing a new treatment called IMNN-001 alongside standard chemotherapy for newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. You would receive either IMNN-001 plus chemotherapy (paclitaxel and carboplatin) or chemotherapy alone, followed by standard maintenance therapy like Olaparib or Niraparib if appropriate. The study aims to see if IMNN-001 is safe and effective, with success measured by how long participants live (Overall Survival) over 48 months. To join, you must be a woman at least 18 years old with a confirmed diagnosis of these specific cancer types. The current recruitment status is unclear.

Study design

This is a randomized, adaptive, open-label, multicenter study with a planned enrollment of 500 participants.

What's involved

You would receive chemotherapy every 3 weeks for 6 cycles. If in the experimental arm, IMNN-001 would be given weekly during most chemotherapy cycles, for a total of 17 treatments.

Compensation

Not stated in the trial record.

Follow-up

The study will measure Overall Survival at 48 months, indicating a follow-up period of at least four years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.